Data / Drug companies / Clinical Solutions Wholesale, LLC
Clinical Solutions Wholesale, LLC: 67 products in the FDA NDC directory, labeler code 58118
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Clinical Solutions Wholesale, LLC (labeler code 58118) lists 67 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 67 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 1, 2025.
The request: Watch Clinical Solutions Wholesale, LLC (FDA labeler code 58118): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 58118
- Products in commercial distribution
- 67
- Packages
- 67
- Finished drugs by generic name
- 14
- Prescription products
- 67
- Over the counter products
- 0
- Controlled substance products
- Schedule III 13, Schedule IV 28, Schedule V 18
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- September 4, 1985
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 61 | 91% |
| Other unapproved drugs | 6 | 9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 67 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pregabalin | 14 | 54 |
| Gabapentin | 8 | 91 |
| Phenobarbital | 6 | 25 |
| Lorazepam | 5 | 38 |
| Alprazolam | 4 | 37 |
| Clonazepam | 4 | 36 |
| Buprenorphine | 4 | 24 |
| Lacosamide | 4 | 57 |
| Clorazepate dipotassium | 3 | 8 |
| Diazepam | 3 | 51 |
| Acetaminophen and codeine phosphate | 2 | 24 |
| Chlordiazepoxide hydrochloride | 2 | 13 |
| Buprenorphine hcl | 2 | 6 |
| Tramadol hydrochloride | 1 | 44 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 42 | 62.7% |
| Capsule | 20 | 29.9% |
| Tablet, film coated | 4 | 6% |
| Tablet, coated | 1 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Benzodiazepine | 21 |
| Partial Opioid Agonist | 11 |
| Opioid Antagonist | 5 |
| Opioid Agonist | 3 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Phenobarbital | 58118-0576 | Tablet | Other unapproved drugs | March 1, 2025 |
| Phenobarbital | 58118-0574 | Tablet | Other unapproved drugs | March 1, 2025 |
| Phenobarbital | 58118-0573 | Tablet | Other unapproved drugs | March 1, 2025 |
| Phenobarbital | 58118-0572 | Tablet | Other unapproved drugs | March 1, 2025 |
| Lorazepam | 58118-0774 | Tablet | Generic drugs (ANDA) | June 25, 2023 |
| Lorazepam | 58118-0773 | Tablet | Generic drugs (ANDA) | June 25, 2023 |
| Pregabalin | 58118-0765 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0764 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0763 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0762 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0761 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0760 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0759 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Pregabalin | 58118-0758 | Capsule | Generic drugs (ANDA) | March 29, 2023 |
| Tramadol Hydrochloride | 58118-2348 | Tablet, coated | Generic drugs (ANDA) | February 13, 2023 |
| Phenobarbital | 58118-1626 | Tablet | Other unapproved drugs | November 30, 2022 |
| Clonazepam | 58118-0154 | Tablet | Generic drugs (ANDA) | April 14, 2022 |
| Clonazepam | 58118-0153 | Tablet | Generic drugs (ANDA) | April 14, 2022 |
| Clonazepam | 58118-0152 | Tablet | Generic drugs (ANDA) | April 14, 2022 |
| Lacosamide | 58118-8815 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2022 |
| Lacosamide | 58118-8814 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2022 |
| Lacosamide | 58118-8813 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2022 |
| Lacosamide | 58118-8812 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2022 |
| Gabapentin | 58118-1167 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
| Gabapentin | 58118-0166 | Tablet | Generic drugs (ANDA) | October 1, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.